Insulin-resistance-improving drug

• US 8,895,011 B2
• Filed: 05/27/2011
• Issued: 11/25/2014
• Est. Priority Date: 05/27/2010
• Status: Active Grant

• Current Assignee: Kohjiro Ueki, Takashi Kadowaki
• Original Assignee: Sekisui Medical Company Limited (Sekisui), University of Tokyo
• Inventors: Kadowaki, Takashi, Ueki, Kohjiro, Okazaki, Yukiko, Bluher, Matthias, Ozawa, Sumiko
• Primary Examiner(s): Gangle, Brian J
• Assistant Examiner(s): MCCOLLUM, ANDREA K
• Application Number:
  US13/699,876
• Publication Number:
  US 20130156793A1
• Time in Patent Office: 1,278 Days
• Field of Search: None
• US Class Current: 424/172.1
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 31/00 Medicinal preparations containing organic active ingredients
• CPC Class Codes: A61K 31/7125 Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
• CPC Class Codes: A61K 38/22 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin A61K38/33, e.g. corticotropin A61K38/35
• CPC Class Codes: A61K 39/3955 against proteinaceous materials, e.g. enzymes, hormones, lymphokines
• CPC Class Codes: A61K 48/005 characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/575 Hormones derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin C07K14/665, e.g. corticotropin C07K14/695
• CPC Class Codes: C07K 16/18 against material from animals or humans
• CPC Class Codes: C07K 2317/76 Antagonist effect on antigen, e.g. neutralization or inhibition of binding
• CPC Class Codes: C12N 15/113 Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing when used in plants C12N15/8218
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12Q 1/686 Polymerase chain reaction [PCR]
• CPC Class Codes: G01N 33/5008 for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
• CPC Class Codes: G01N 33/6893 related to diseases not provided for elsewhere

Abstract

Provided are a means for the prevention and treatment of obesity and/or insulin resistance and, particularly, pharmaceutical drugs for the treatment of obesity and/or insulin resistance under the influence of Follistatin-like 3 (FSTL3). Specifically, provided is an insulin resistance improving drug comprising an FSTL3 inhibitor as an active ingredient, particularly, the insulin resistance improving drug, wherein the FSTL3 inhibitor is one of (A) a substance specifically binding to FSTL3 to inhibit or suppress a function of FSTL3, (B) an inhibitor for expression of FSTL3, and (C) a competitor of FSTL3.

Claims

1. A method for decreasing insulin resistance in a patient comprising:

the step of administering to a patient with insulin resistance an effective amount of a Follistatin-like 3 (FSTL3) inhibitor, wherein the FSTL3 inhibitor is

one or more of activin B or activin AB.

2. The method of claim 1, wherein the administration of the inhibitor further comprises administering a pharmaceutically acceptable diluent or carrier with the one or more of activin B or activin AB.

3. A method for decreasing insulin resistance in a patient consisting of the step of:

administering to a patient with insulin resistance, solely or in combination with another drug, an effective amount of a composition comprising Follistatin-like 3 (FSTL3) inhibitor, wherein the FSTL3 inhibitor is

one or more of activin B or activin AB,

and the composition further comprises one or more pharmaceutically acceptable diluents, carriers, additives, or excipients.

4. A method for decreasing insulin resistance in a patient comprising the step of:

administering to a patient with insulin resistance a pharmaceutical composition consisting of;

an effective amount of a Follistatin-like 3 (FSTL3) inhibitor, wherein the FSTL3 inhibitor is

one or more of activin A, activin B or activin AB, and

one or more pharmaceutically acceptable diluents, carriers, additives, or excipients.